Welcome!
About Us
The SomaScan & Biomarker Core, established within the Genomic Medicine Institute (GMI) under the leadership of Dr. Russell Bowler, provides cutting-edge proteomic and biomarker analysis services to support Cleveland Clinic investigators and external collaborators. This Core reflects GMI’s broader mission to advance precision medicine and genomics through high-impact research, emphasizing discovery across molecular pathways and disease areas.
Dr. Bowler, Chair of GMI and a recognized leader in proteomics and translational research, launched the Core to expand access to comprehensive protein and biomarker profiling technologies. These resources enaresearchers to measure thousands of proteins simultaneously and unbiasedly, facilitating breakthroughs in disease mechanisms, diagnostics, and therapeutic development.
Mission Statement
Our mission is to empower the scientific community with state-of-the-art proteomic and biomarker platforms that enable comprehensive, unbiased biological discovery and targeted analysis. We are committed to advancing translational research and precision medicine through collaboration, innovation, and data-driven insights.
History of the Core
The SomaScan & Biomarker Core was established in 2025 as part of GMI’s strategic expansion into proteomics and biomarker sciences. Recognizing the growing importance of protein-level analyses in complementing genomic research, GMI launched this facility to provide centralized, high-throughput, and scalable proteomic services to meet the evolving needs of investigators across the Cleveland Clinic and beyond.
The Core builds on Dr. Bowler’s extensive expertise in proteomics and systems biology, providing Cleveland Clinic researchers with local access to global-standard proteomic tools.
Services Offered
Our facility offers two primary service platforms:
1. SomaScan® Plasma Proteomics Assays (7k and 11k panels)
- High-throughput, unbiased measurement of 7,000 or 11,000 proteins from plasma and other biological fluids.
- Broad coverage across all major biological pathways, including immune, metabolic, cardiovascular, neurological, and oncologic systems.
- Allows systems-level discovery of protein biomarkers, signaling networks, and disease-associated pathways.
2. Targeted Protein and Biomarker Assays (A la carte services)
- Customizable, focused analysis of specific biomarkers or panels of interest.
Platforms include:
Meso Scale Discovery (MSD) for multiplexed immunoassays.
Luminex® bead-based assays for simultaneous detection of multiple analytes.
Additional targeted platforms as needed.
Our team provides consultation and collaboration at every stage, from experimental design through data interpretation, ensuring optimal alignment with your research goals.
| Maria Khrestian | Lead Research Technologist | 216.445.8584 | khrestm@ccf.org |
| Tammy Sadler | Research Lab Manager | 216.445.8584 | sadlert@ccf.org |
| Russell Bowler | Director / Staff | 216.444.2048 | bowlerr@ccf.org |
| Gili Ornan | Department Administrator | 216.445.8584 | ornang@ccf.org |
| Hours | Location | |
|
9500 Euclid Avenue NE5-231 Cleveland, OH 44195 |
]| Name | Role | Phone | Location | |
|---|---|---|---|---|
| General Inquiries |
somascan@ccf.org
|
